PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated

Seaport dosed the first patient in a Phase 2a GlyphAgo trial for anxiety in Australia.

What the company is saying

PureTech Health plc (LSE:PRTC) reports that its Founded Entity, Seaport Therapeutics (NASDAQ:SPTX), has started dosing patients in a Phase 2a clinical trial of GlyphAgo (SPT-320) in Australia for adults with generalized anxiety disorder (GAD) and sleep disturbance. The company frames this as a major milestone, emphasizing the unmet need in GAD, which affects more than 300 million people globally. Seaport highlights GlyphAgo as a novel oral prodrug of agomelatine, designed to improve bioavailability and reduce liver exposure compared to the approved 25 mg agomelatine dose. Executives Daphne Zohar (CEO) and Daniel Bonner, Ph.D. (SVP, Platform) are named and quoted, stressing the innovation and potential impact for patients. The announcement underscores strong Phase 1 pharmacokinetic results, including a 6.8-fold increase in bioavailability and no serious or liver-related adverse events. Seaport also outlines plans for a global Phase 2/3 trial in the first half of 2027, with topline data from both trials expected in 2028. The tone is confident and forward-looking, with repeated references to the scale of the clinical need and the potential for GlyphAgo to become a leading treatment.

What the data suggests

The company has initiated a six-week, double-blind Phase 2a trial in Australia, randomizing patients to 16 mg/day (5 mg agomelatine) or 32 mg/day (10 mg agomelatine) doses of GlyphAgo. The trial’s primary endpoint is proof-of-pharmacology on sleep, with secondary endpoints including anxiety severity (HAM-A), illness severity (CGI-S), safety, tolerability, and pharmacokinetics. Phase 1 data showed GlyphAgo achieved a 6.8-fold increase in bioavailability over unmodified agomelatine, surpassing the two-fold target, and delivered geometric mean agomelatine AUC 0-24 at or above the approved 25 mg dose, with 10-fold lower inter-subject variability. No serious, severe, or liver-related adverse events were observed in Phase 1. Agomelatine is already approved for GAD in Australia and for major depressive disorder in Australia and the EU. The company expects topline Phase 2a data in early 2028 and plans a global Phase 2/3 trial in 2027, with results by end-2028. No financial results, revenue, or cash position are disclosed, but the company signals a need for substantial additional funding to complete development.

Analysis

The announcement is positive in tone, highlighting the dosing of the first patient in a Phase 2a trial and strong Phase 1 pharmacokinetic results. However, the majority of the value-driving claims are forward-looking: topline Phase 2a data are not expected until early 2028, and a global Phase 2/3 trial is only planned for 2027 with results by end-2028. The release references the need for substantial additional funding, but provides no detail on committed capital or financial runway. While the Phase 1 data are specific and credible, the announcement includes aspirational statements about GlyphAgo's potential impact and market leadership that are not yet substantiated by clinical efficacy data. The gap between narrative and evidence is moderate: realised progress is limited to early-stage clinical milestones, while commercial and clinical benefits are several years away and contingent on future trial success and funding. No profitability, revenue, or cash flow data are disclosed, as expected for a biotech at this stage.

Risk flags

• ●Execution risk is high: both the Phase 2a and planned Phase 2/3 trials are multi-year efforts, with topline data not expected until 2028, leaving significant time for potential setbacks or delays.
• ●Financial risk is material: the company explicitly states a need for substantial additional funding to complete development and commercialize GlyphAgo, but no details on current cash position or committed capital are provided.
• ●Clinical risk remains: while Phase 1 pharmacokinetic and safety data are positive, there is no efficacy data in GAD patients yet, and success in early-stage trials does not guarantee positive results in larger, later-stage studies.
• ●Regulatory risk is present: GlyphAgo is a novel prodrug, and while agomelatine is approved in Australia and the EU, the new formulation will require full regulatory review and could face unforeseen hurdles.
• ●Market risk exists: the announcement references the large addressable population (over 300 million affected globally), but provides no data on market access, competitive positioning, or payer acceptance, all of which could impact commercial viability.

Bottom line

Seaport Therapeutics, backed by PureTech Health, has begun dosing in a Phase 2a trial of GlyphAgo for GAD and sleep disturbance in Australia, with topline data not expected until early 2028. The Phase 1 data are promising for bioavailability and safety, but there is no efficacy data in patients yet, and all commercial value is several years away. The company is clear that substantial additional funding will be needed to advance through late-stage trials and potential commercialization. Investors should recognize that the scientific rationale is strong, but the timeline is long and the risks—clinical, financial, and regulatory—are significant. The most important takeaway is that this is an early clinical milestone in a multi-year process, with no near-term revenue or product impact. The next key disclosure will be any interim clinical data or funding updates before 2028.

Announcement summary

(LSE:PRTC) PureTech Health plc announced that its Founded Entity, Seaport Therapeutics (NASDAQ:SPTX), has dosed the first patient in a Phase 2a clinical trial in Australia evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in adults with generalized anxiety disorder (GAD) and sleep disturbance. The six-week, double-blind trial randomizes patients to receive either 16 mg/day (containing approximately 5 mg agomelatine) or 32 mg/day (containing approximately 10 mg agomelatine) of GlyphAgo. The primary objective is to establish proof-of-pharmacology by assessing the effects of GlyphAgo on sleep, using patient-reported outcomes such as the Insomnia Severity Index (ISI) and EEG-based sleep architecture measures. Additional endpoints include anxiety severity (Hamilton Anxiety Scale, HAM-A), overall illness severity (Clinical Global Impression-Severity, CGI-S), safety, tolerability, and pharmacokinetics. Topline data from the Phase 2a trial are expected in early 2028. GlyphAgo is a novel, "Glyphed" oral prodrug of agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist. In Phase 1, GlyphAgo demonstrated a statistically significant 6.8-fold increase in bioavailability compared to unmodified agomelatine, exceeding the program's pre-specified two-fold target. At doses delivering approximately 5 mg or 10 mg agomelatine, GlyphAgo achieved geometric mean agomelatine AUC 0-24 at or above that observed with the approved 25 mg dose of unmodified agomelatine, with geometric CV% for agomelatine AUC 0-24 approximately 10-fold lower than that of agomelatine 25 mg. No serious or severe adverse events, no liver-related adverse events, and no clinically significant changes in liver-related laboratory parameters (ALT, AST, or bilirubin) were observed in Phase 1. Agomelatine is approved for the treatment of GAD in Australia and major depressive disorder in Australia and the European Union. Published meta-analyses indicate agomelatine ranked highest for efficacy and tolerability relative to benzodiazepines and SSRIs in GAD. Seaport Therapeutics plans to initiate a global, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of GlyphAgo in GAD in the first half of 2027, with topline data expected by the end of 2028. Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics, and Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics, are named executives quoted in the announcement. The company notes that anxiety disorders affect more than 300 million people globally.

Disagree with this article?